Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discoverers resolve breast cancer gene inventorship:

This article was originally published in Clinica

Executive Summary

The organisations involved in the discovery of the tumour suppressor gene, BRCA1, have reached an agreement on inventorship. The US NIH, the University of Utah and Myriad Genetics (US) have signed a document that names all three institutions as joint inventors under the leadership of Dr Mark Skolnick, who works for both Myriad and the University. The agreement also confirms that commercial rights remain with Myriad and its licensees, Eli Lilly (US) and Hybritech (US). Mutations in BRCA1 are involved in both breast and ovarian cancer.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts